• Proportion of patients achieving hematologic and molecular complete response (CR) after induction chemotherapy and imatinib mesylate [ Designated as safety issue: No ]
  
• Duration of hematologic CR [ Designated as safety issue: No ]
  
• Durations of hematologic and molecular CR after hematopoietic stem cell transplantation [ Designated as safety issue: No ]
  

• Overall survival [ Designated as safety issue: No ]
  
• Clinical toxicities [ Designated as safety issue: Yes ]
  
• Prognostic factors in patients treated with this regimen [ Designated as safety issue: No ]
  

OBJECTIVES:

Primary

• To determine the clinical efficacy of imatinib mesylate and combination chemotherapy in terms of complete response (CR) rate (both hematologic and molecular), CR duration, and overall survival in patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia.
• To determine the toxicities of this regimen in these patients.

Secondary

• To establish the prognostic factors in patients treated with this regimen.

OUTLINE: This is a multicenter study. Patients are stratified according to age (64 or less vs 65 or over).

• Induction chemotherapy: Patients receive daunorubicin hydrochloride IV continuously over 24 hours on days 1-3, vincristine IV on days 1 and 8, and oral prednisolone on days 1-14. Treatment repeats for 5 courses in the absence of disease progression or unacceptable toxicity.
• Imatinib mesylate administration: Patients also receive oral imatinib mesylate once daily beginning on day 8 of course 1 induction chemotherapy and continuing for up to 2 years.
• Consolidation chemotherapy: Patients receive daunorubicin hydrochloride IV continuously over 24 hours on days 1-2, vincristine IV on days 1 and 8, and oral prednisolone on days 1-14 in course 1; cytarabine IV over 2 hours and etoposide IV over 3 hours on days 1-4 in courses 2 and 4; and methotrexate IV continuously over 36 hours on days 1-2 and 15-16 and leucovorin calcium IV every 6 hours x 3 doses followed by oral leucovorin calcium until methotrexate levels are < 0.05 micromol/L in courses 3 and 5. Treatment continues in the absence of disease progression or unacceptable toxicity. Patients with available HLA-matched sibling or unrelated hematopoietic cell donors or HLA-nonidentical familial hematopoietic cell donors proceed to allogeneic hematopoietic stem cell transplantation (HSCT). Patients who are without hematopoietic cell donors and who remain in hematologic remission continue to receive maintenance therapy with oral imatinib mesylate.
• Allogeneic HSCT: Patients undergo HSCT.
• CNS prophylaxis: Patients receive six doses of intrathecal (IT) methotrexate and hydrocortisone beginning on the first day of each chemotherapy course. Patients with CNS disease at diagnosis receive intensified CNS therapy comprising 10 doses of IT methotrexate and cranial irradiation after bone marrow remission is achieved.

After completion of study treatment, patients are followed periodically.

DISEASE CHARACTERISTICS:

• Acute lymphoblastic leukemia (ALL) or acute mixed lineage leukemia

  • Newly diagnosed disease

  • Philadelphia-chromosome positive (Ph+) acute lymphoblastic leukemia or Ph+ acute mixed lineage leukemia

    • Positive result for RT-PCR for Bcr-Abl transcript (Ph+ ALL or Philadelphia-chromosome positive acute mixed lineage leukemia)

PATIENT CHARACTERISTICS:

• Bilirubin < 2 mg/dL
• SGOT < 3 times upper limit of normal
• Creatinine < 2.0 mg/dL
• Ejection fraction > 45% by MUGA scan
• Not nursing
• Fertile patients must use effective contraception
• No known sensitivity to study drugs
• No severe medical conditions that, in the view of the investigator, prohibits participation in the study

PRIOR CONCURRENT THERAPY:

• No other investigational agents in the past 30 days